|
Published by: Datamonitor
Published: Mar. 18, 2003 - 431 Pages
Table of Contents
CHAPTER 1 Executive summary
1.1 Scope
1.2 Datamonitor insight into the anti-hypertensives market
1.3 Key metrics
CHAPTER 2 Market definition
2.1 Market definition
2.2 Epidemiology overview
2.3 Anti-hypertensive drug class definitions
CHAPTER 3 Global analysis by drug class
3.1 Overview of global anti-hypertensives market
3.2 Future impact of the ALLHAT trial
CHAPTER 4 ACE inhibitor global analysis
4.1 Overview of the global ACE inhibitor market
4.2 Five-year trends in the global ACE inhibitor market
4.3 ACE inhibitor brand analysis
4.4 Comparison of key brands in the ACE inhibitor class
CHAPTER 5 CCB global analysis
5.1 Overview of the global CCB market
5.2 Five-year trends in the global CCB market
5.3 CCB brand analysis
5.4 Comparative forecasts
CHAPTER 6 ARB global analysis
6.1 Overview of the global ARB market
6.2 Five-year trends in the global ARB market
6.3 Angiotensin receptor blocker brand analysis
6.4 Comparison of key brands in the ARB class
CHAPTER 7 Beta blocker global analysis
7.1 Overview of the global beta blocker market
7.2 Five-year trends in the global beta blocker market
7.3 Beta blocker brand analysis
7.4 Comparison of key brands in the beta blocker class
CHAPTER 8 Diuretics
8.1 Impact of the ALLHAT trial
8.2 Inspra (eplerenone)
CHAPTER 9 Minor classes global analysis
9.1 Alpha blockers
9.2 Centrally-acting anti-hypertensives
CHAPTER 10 Comparative forecasts
CHAPTER 11 Country analysis
11.1 Significance of major countries in the global anti-hypertensives market
11.2 The US anti-hypertensives market
11.3 Japan anti-hypertensives analysis
11.4 France anti-hypertensives analysis
11.5 Germany anti-hypertensives analysis
11.6 Italy anti-hypertensives analysis
11.7 Spain anti-hypertensives analysis
11.8 UK anti-hypertensives analysis
CHAPTER 12 Appendix A
12.1 Classification of hypertension
12.2 Treatment guidelines
12.3 Table of tables
12.4 Table of figures
12.5 Bibliography
12.6 Epidemiology sources and methodology
12.7 Sales data research methodology
CHAPTER 13 Appendix B
13.1 About Datamonitor
13.2 Datamonitor Healthcare’s therapy area capabilities
DATASETS
Table 1: Global sales forecasts for the anti-hypertensives market, 2002-2010
Table 2: Global sales forecasts for the ARBs, 2002-2010
Table 3: Prevalence of hypertension in the seven major markets in 2002, broken down by age
Table 4: Prevalence of smoking, adults aged 15 and over, by sex, 1999
Table 5: Number of hours spent participating in various physical activities in a typical week, adults aged 15 and over, 1997
Table 6: Alcohol consumption in the seven major markets, 1998-2000
Table 7: Summary of key facts concerning the different anti-hypertensives classes
Table 8: Global sales in the anti-hypertensives market by drug class, 2000-2002
Table 9: Sales growth in the anti-hypertensives market, 1998-2002
Table 10: Clinical outcomes in the ALLHAT trial by treatment group
Table 11: Results of the ANBP2 study
Table 12: Leading ACE inhibitor fact file
Table 13: Global sales of the leading branded ACE inhibitors, 2000 -2002
Table 14: Sales growth in the ACE inhibitor class, 1998-2002
Table 15: Prinivil/Zestril: key facts
Table 16: Forecast global revenues for Prinivil and Zestril 2002-2010
Table 17: Impacting factors on the revenues of Prinivil and Zestril, 2002-2010
Table 18: Altace: key facts
Table 19: Global sales forecasts for Aventis’ and King’s brands of Altace (ramipril), 2002-2010
Table 20: Impacting factors on the revenues of the Altace brands, 2002-2010
Table 21: Lotrel: key facts
Table 22: Total global sales forecasts for Lotrel (benazepril/amlodipine), 2002-2010
Table 23: Impacting factors on the revenues of Lotrel, 2002-2010
Table 24: Global sales forecasts for the ACE inhibitors, 2002-2010
Table 25: CCB key facts
Table 26: Global sales of the leading branded CCBs, 2000-2002
Table 27: Sales growth in the CCB class, 1998-2002
Table 28: Norvasc: key facts
Table 29: Global sales forecasts for Norvasc (amlodipine), 2002-2010
Table 30: Impacting factors on the revenues of Norvasc, 2002-2010
Table 31: Global sales forecasts for the CCBs, 2002-2010
Table 32: ARB fact file
Table 33: Global sales of the leading branded ARBs, 2000-2002
Table 34: Sales growth in the ARB class, 1998-2002
Table 35: Key clinical completed and ongoing clinical trials for the ARBs by indication
Table 36: Cozaar: key facts
Table 37: Life trial results
Table 38: LIFE trial diabetic sub-group analysis
Table 39: OPTIMAAL major efficacy endpoints
Table 40: Global sales forecasts for Cozaar (losartan) and Nu-Lotan (losartan), 2002-2010
Table 41: Impacting factors on the revenues of Cozaar and Nu-Lotan, 2002-2010
Table 42: Diovan: key facts
Table 43: Global sales forecasts for Diovan (valsartan), 2002-2010
Table 44: Impacting factors on the revenues of Diovan, 2002-2010
Table 45: Avapro: key facts
Table 46: Global sales forecasts for Avapro (irbesartan), 2002-2010
Table 47: Impacting factors on the revenues of Avapro, 2002-2010
Table 48: Blopress/Atacand: key facts
Table 49: Global sales forecasts for Blopress (candesartan) and Atacand (candesartan), 2002-2010
Table 50: Impacting factors on the revenues of Blopress and Atacand, 2002-2010
Table 51: Micardis: key facts
Table 52: SBP and DBP reductions with telmisartan and losartan, 18-24 hours after dosing
Table 53: Global sales forecasts for Micardis (telmisartan), 2002-2010
Table 54: Impacting factors on the revenues of Micardis, 2002-2010
Table 55: Teveten: key facts
Table 56: Global sales forecasts for Teveten (eprosartan), 2002-2010
Table 57: Impacting factors on the revenues of Teveten, 2002-2010
Table 58: Global sales forecasts for Benicar (olmesartan), 2002-2010
Table 59: Impacting factors on the revenues of Benicar, 2002-2010
Table 60: Global sales forecasts for the ARBs, 2002-2010
Table 61: Beta blocker fact file
Table 62: Global sales of the leading branded beta blockers, 2000-2002
Table 63: Sales growth in the beta blocker class, 1998-2002
Table 64: Seloken: key facts
Table 65: Global sales forecasts for Seloken (metoprolol), 2002-2010
Table 66: Impacting factors on the revenues of Seloken, 2002-2010
Table 67: Coreg / Dilatrend: key facts
Table 68: Risk reduction of carvedilol in patients with ejection fractions above and below 15% in COPERNICUS
Table 69: Results of the BRING-UP study
Table 70: Global sales forecasts for Coreg (carvedilol) and Dilatrend (carvedilol), 2002-2010
Table 71: Impacting factors on the revenues of Coreg and Dilatrend, 2002-2010
Table 72: Concor/Ziac: key facts
Table 73: Global sales forecasts for Concor (bisoprolol), 2002-2010
Table 74: Impacting factors on the revenues of Concor, 2002-2010
Table 75: Global sales forecasts for the beta blockers, 2002-2010
Table 76: Summary of recent eplerenone clinical trials, 2002
Table 77: Global sales forecasts for Inspra (eplerenone), 2002-2010
Table 78: Impacting factors on the revenues of Inspra, 2002-2010
Table 79: Alpha blocker fact file
Table 80: Global sales of the leading branded alpha blockers, 2000-2002
Table 81: Sales growth in the alpha blocker class, 1998-2002
Table 82: Global sales of the leading branded centrally-acting anti-hypertensives, 2000 to 2001
Table 83: Sales growth in the centrally-acting anti-hypertensives class, 1998-2001
Table 84: Global sales forecasts for the anti-hypertensives market, 2002-2010
Table 85: Breakdown of the global anti-hypertensives market by country, 2000-2001
Table 86: Breakdown of anti-hypertensives sales by drug class in the seven major markets, 2001
Table 87: Top 10 anti-hypertensives in the US in 2000-2002
Table 88: Sales of the ARBs in the US, 2000-2002
Table 89: Promotional spending for prescription drugs in the US, 1996-2000
Table 90: Top 10 anti-hypertensives in Japan, 2001
Table 91: Sales of the ARBs in Japan, 2000-2001
Table 92: Top 10 anti-hypertensives in France 2001
Table 93: Sales of the ARBs in France, 2000-2001
Table 94: Top 10 anti-hypertensives in Germany in 2001
Table 95: Sales of the ARBs in Germany, 2000-2001
Table 96: Top 10 anti-hypertensives in Italy, 2001
Table 97: Sales of the ARBs in Italy, 2000-2001
Table 98: Combined sales of four ARB generics, 2001
Table 99: Patient co-payment classification in Italy, 2002
Table 100: Top 10 anti-hypertensives in Spain, 2001
Table 101: Sales and growth of the ARB brands in Spain, 2000-2001
Table 102: Total sales of the six ARB molecules, 2000-2001
Table 103: Top 10 anti-hypertensives in the UK, 2000-2001
Table 104: Sales of the ARBs in the UK, 2000-2001
Table 105: US JNC risk stratification and treatment for high blood pressure
Table 106: Confidence ratings for market sizes
Table 107: Confidence ratings for sales figures
Table 108: Confidence ratings for global sales of the leading branded ACE inhibitors
Table 109: Confidence ratings for global sales of the leading branded CCBs, 2001
Table 110: Confidence ratings for global sales of the leading branded ARBs, 2001
Table 111: Confidence ratings for global sales of the leading branded beta blockers, 2001
Table 112: Confidence ratings for global sales of the leading branded alpha blockers, 2001
Table 113: Global sales of the leading branded centrally-acting anti-hypertensives
Table 114: Confidence ratings for the sales of the top 10 anti-hypertensives in the US, 2001
Table 115: Confidence ratings for sales of the ARBs in the US, 2001
Table 116: Confidence ratings for sales of the top 10 anti-hypertensives in Japan, 2001
Table 117: Confidence ratings for sales of ARBs in Japan, 2001
Table 118: Confidence ratings for sales of the top 10 anti-hypertensives in France, 2001
Table 119: Confidence ratings for sales of ARBs in France, 2001
Table 120: Confidence ratings for sales of the top 10 anti-hypertensives in Germany, 2001
Table 121: Confidence ratings for sales of ARBs in Germany, 2001
Table 122: Confidence ratings for the sales of the top 10 anti-hypertensives in Italy, 2001
Table 123: Confidence ratings for sales of ARBs in Italy, 2001
Table 124: Confidence ratings for sales of the top 10 anti-hypertensives in Spain, 2001
Table 125: Confidence ratings for sales of ARBs in Spain, 2001
Table 126: Confidence ratings for the sales of the top 10 anti-hypertensives in the UK, 2001
Table 127: Confidence ratings for sales of ARBs in the UK, 2001
Table 128: Exchange rates used in this report, 2001
AbstractIntroduction:
At the end of 2002, the long-awaited ALLHAT trial results were published with study investigators identifying genericized diuretics as the first-line therapy of choice. In addition, over the period to 2010, several major patent challenges and expiries threaten to impact the market heavily, with future growth being almost entirely dependent on the results of ongoing clinical trials for the ARBs.
Scope:
* Critical insight into the competitive positioning of leading brands and the future direction of the market, including forecasts to 2010.
* In-depth analysis of the market impact of the ALLHAT results and the opportunities that remain for branded products in this highly genericized market.
* Evaluation of the most likely outcomes and implications of the major ongoing clinical trials, focusing on ARBs as the key drivers of market growth.
* Assessment of the lessons that companies with developmental agents can learn from the experience of currently marketed products.
Report Highlights:
Despite the ALLHAT results, a weak hypertension R&D pipeline and major patent expiries, continued uptake of the ARBs is forecast to drive the value of the global anti-hypertensives market from $36.8bn in 2002 to $51.3bn in 2010.
Sales of ARBs are forecast to increase from $7.4bn in 2002 to $24.0bn in 2010 as a result of their superior side effect profile, the availability of long-term data and approval for additional indications.
Sales of Diovan will rise to $6.0bn by 2010, overtaking Cozaar to lead the ARB class in 2004 and Norvasc to lead the anti-hypertensives market in 2005. However, combined sales of the candesartan brands, Atacand and Blopress will overtake those of Diovan.
Reasons to Purchase:
* Identify the most appropriate response to the ALLHAT results and the recommendations for diuretics to be used as first-line therapy.
* Understand how to maximize the potential of branded products in this highly genericized and competitive market.
* Improve competitive positioning by responding appropriately to market threats and forecasting the future direction of the market.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
